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Abstract Glucocorticoids (GC) are lipophilic hormones
commonly used as therapeutics in acute and chronic
inflammatory disorders such as inflammatory bowel disease
due to their attributed anti-inflammatory and immunosup-
pressive actions. Although the adrenal glands are the major
source of endogenous GC, there is increasing evidence for
the production of extra-adrenal GC in the brain, thymus,
skin, vasculature, and the intestine. However, the physiolog-
ical relevance of extra-adrenal-produced GC remains still
ambiguous. Therefore, this review attracts attention to dis-
cuss possible biological benefits of extra-adrenal-synthesized
GC, especially focusing on the impact of locally synthesized
GC in the regulation of intestinal immune responses.
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Maintenance of intestinal immune homeostasis—a
delicate balance
The intestinal tract exhibits the largest mucosal surface of
the human body covering an area of almost 200 m2 [1].
This enormous surface is not only in constant contact with
harmless commensal bacteria and food antigens but also
with potentially harmful pathogens, such as viruses,
bacteria, fungi or parasites. Critically, in the intestine, the
outside world, colonized with various microorganisms, and
the (generally sterile) inside world, i.e., the intestinal tissue,
are separated only by a single layer of epithelial cells. This
close contact with bacteria and tissue represents several
potential problems [2]. On one hand, the epithelial barrier
function is easily impaired enabling intestinal bacteria to
invade the underlying tissue and potentially even the entire
body, leading to life-threatening bacteremia. On the other
hand, the close contact between non-self antigens and
immune cells may also trigger a chronic stimulation of
intestinal immune cells resulting in devastating inflammatory
disorders [3]. Given the fact that the intestinal epithelial and
subepithelial layer is home of approximately 70% of all
lymphocytes in our body and also a large number of innate
immune cells, this is not only an academic reflection but
concerns a real constant threat [4]. In light of this side-by-
side closeness of immune cells and the intestinal flora with
great immuno-stimulatory potential, the intestinal immune
system has to find the appropriate balance between protec-
tive immune responses and tolerance.
A complex network of nonhematopoietic cells and
highly adapted cells of the innate and adaptive immune
system normally prevents the penetration of luminal
antigens, commensal bacteria, and pathogens [5]. A first
line of physical defense, the intestinal epithelial barrier, is
formed by a single layer of intestinal epithelial cells
displaying numerous physical and biochemical adaptations
to separate the underlying intestinal tissue from the luminal
space [6]. These include the formation of intercellular tight
junctions (TJ), the release of mucus from goblet cells, and
the secretion of a broad range of antimicrobial peptides.
Furthermore, trans-epithelial transportation of IgA to the
lumen further helps to protect the epithelial layer from
bacterial invasion [7]. As discussed later on, intestinal
epithelial cells are also a source of immunoregulatory
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factors, which participate in the control of intestinal
immune responses [8]. Minimal alterations in the integrity
of the intestinal epithelial barrier, evoked by various
physical and pharmacological triggers, as well as primary
defects in intestinal epithelial barrier proteins, may lead to
the induction of severe intestinal disorders such as
inflammatory bowel disease (ulcerative colitis or Crohn's
disease in humans). In addition to this physical barrier, the
intestinal mucosa contains an extensive and complex
immune system, usually confirming hyporesponsiveness
or tolerance towards commensal bacteria while maintaining
the ability to fight pathogenic microorganisms [9, 10].
Intense communication between the intestinal epithelium
and cells of the innate and adaptive immune system is
critical to achieve proper function of the intestinal immune
system, warrant host protection, and avoid unnecessary
inflammation-associated damage [11].
Dysregulation of the balance between tolerance and
immunity leads to severe pathogenesis in the intestinal
tract, including inflammatory bowel disease (IBD), and
chronic inflammatory responses may result in the develop-
ment of intestinal cancer. A hallmark of the adaptive
intestinal immune system is the relatively high number of
regulatory immune cells within the lamina propria. Regu-
latory T cells (T reg) and the associated secretion of
immunosuppressive cytokines such as IL-10 or TGFβ have
been ascribed a major role in the maintenance of intestinal
immune homeostasis [12, 13]. Adoptive transfer of T reg
not only prevents the development of experimental colitis
in various animal models but also ameliorates established
disease [14]. Furthermore, it has been shown that animals
deficient in the production of IL-10 or TGFβ develop
chronic intestinal inflammation [15]. Beside these and other
well-known immunoregulatory mechanisms contributing to
the maintenance of intestinal homeostasis, the synthesis of
immunosuppressive glucocorticoids (GC) by intestinal
epithelial cells seems to represent a novel and important
mechanism in the maintenance of intestinal immune
homeostasis [16]. In this review, we will discuss various
aspects of GC synthesis in the intestinal epithelium and
their action on local immune cells.
Actions and anti-inflammatory properties of GC
GC exert a variety of important anti-inflammatory actions.
Apart their crucial role in glucose metabolism and blood
pressure regulation, GC are very important regulators of
immune reactions [17, 18]. Depending on where and when
GC act on target cells, the anti-inflammatory and immuno-
regulatory properties of GC may be mediated by different
mechanisms. GC normally interact and bind to their
corresponding glucocorticoid receptor (GR) in the cyto-
plasm. The inactive GR is coupled to a protein complex
including two subunits of the heat shock protein 90 (hsp90)
acting as chaperones to prevent nuclear translocalization of
unoccupied GR. Upon binding of GC, the GR dissociates
from hsp90 leading to nuclear translocation of the GC/GR
complex. The agonist-induced translocation of the GR to
the nucleus is illustrated in Fig. 1. In the nucleus, this
complex binds to specific DNA sequences in the promoter
regions of target genes, so-called GC response elements
[19], or to other proteins (mostly transcription factors), and
thereby either increases (transactivation) or decreases
(transrepression) the expression of responsive genes. GC/
GR complexes increase gene transcription through chroma-
tin remodeling and recruitment of RNA polymerase II by
interacting with co-activator proteins, such as steroid
receptor co-activator-1 (SRC-1), leading to an enhancement
of histone acetyl transferase activity. Local changes in DNA
or chromatin configurations through GC/GR interactions,
that might be previously masked, lead to an increase in
binding of transcription factors and additionally to a more
stable transcription initiation complex [20].
Various immunoregulatory functions of GC seem to act
via distinct molecular targets. One of the most important
activities of GC is their inhibitory effect on the production
of pro-inflammatory cytokines, as for example IL-1β, IL-6,
IL-12, TNFα, INFγ, and others [21, 22]. This inhibition is
most probably mediated through direct interaction with the
transcription factors AP-1 or NFκB [23–25]. NFκB is
activated through a number of cytokines, such as TNFα or
IL-1β, UV irradiation, stress, and bacterial and viral
infections. The transcriptional activity of NFκB can be
modulated by GC bound to the GR by physical interaction
with the active trans-activating p65 RelA subunit of NFκB,
leading to the hindrance of NFκB binding to the appropri-
ate DNA recognition motifs in promoter regions of different
target genes [26]. Furthermore, GC have been demonstrated
to increase the rate of IκB (inhibitor of NFκB) protein
synthesis, which in turn traps the activation of NFκB. In
addition, direct protein–protein interactions between GR
Fig. 1 Ligand-induced translocation of the glucocorticoid receptor.
HEK cells were transfected with a fluorescence-labeled glucocorticoid
receptor (hGR-DsRed2), and nuclear translocation was induced by
addition of cortisol. N nucleus, C cytoplasm
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and AP-1, STAT3, STAT5, and STAT6 have been reported
indicating a modulation of binding or activation of these
transcription factors resulting in a modified expression of
inflammatory genes [27]. Finally, it should not be overseen
that GC are potent inducers of apoptosis in a variety of
immune cells [28, 29]. GC-mediated apoptosis may be
either induced by inhibiting the expression of NFκB-
induced anti-apoptotic molecules or the direct induction of
the pro-apoptotic Bcl-2 homolog Bim [30–32]. Notably,
many immune cells are strongly resistant to GC-induced
apoptosis in the absence of Bim [31]. Due to these
immunoregulatory and anti-inflammatory properties, GC
are widely used in clinical applications ranging from
preventing rejection of transplants, treatment of allergic
asthma and rheumatoid arthritis, to highly effective use in
IBD [33–36].
The adrenals: a small organ with an enormous
steroid-producing capacity
GC are lipid hormones synthesized from the precursor
cholesterol through sequential conversions by members of
the cytochrome P450 (CYP) superfamily and 3β-
hydroxysteroid dehydrogenase (3βHSD) to cortisol in
humans and corticosterone in rodents [37].
GC synthesis and release from adrenal glands is
predominantly regulated by the hypothalamus–pituitary–
adrenal axis [38]. The release of corticotropin-releasing
hormone from the paraventricular nucleus located in the
hypothalamus directly stimulates the secretion of
adrenocorticotropin-releasing hormone (ACTH) in the
anterior pituitary gland. ACTH reaches the adrenal cortex
via the blood stream and binds to G-protein-coupled ACTH
receptors on the surface of cells in the zona reticularis.
ACTH induces the activation of adenylate cyclase leading
to a subsequent increase in intracellular cAMP levels
having pleiotropic functions such as the activation of
protein kinase A [39]. cAMP response elements (CRE) in
turn are found in the promoter region of a variety of
steroidogenic genes, mediating GC synthesis induction in
response to these pathways [40]. Adrenal GC synthesis is
able to respond very rapidly to a variety of triggers, often
within minutes, and thus provides the body with appropri-
ate levels of GC. Adrenal-derived GC are crucially
involved in glucose metabolism, insulin release for blood
sugar maintenance, regulation of blood pressure, as well as
the maintenance of immune homeostasis [41]. Therefore,
adrenal insufficiency, characterized by lack of endogenous
GC synthesis as observed in Addison disease, or adrenal-
ectomy results in hypoglycemia, hypotension, and in-
creased susceptibility to inflammatory and autoimmune
disorders [42]. On the other hand, chronic treatment with
therapeutic doses of GC results in immune suppression and
opportunistic infections with microorganisms. The protec-
tive effect of endogenous GC against the lethal effect of
high-dose endotoxins, IL-1β, and TNFα has been known
for a long time. Thus, not surprisingly, adrenalectomy or
inhibition of systemic GC synthesis by specific inhibitors
results in rapid death by shock after induction of strong
immune responses [43–45].
GC—not only produced in the adrenals
The lack of serum GC in adrenalectomized animals
strongly supports the role of adrenal glands as the major
source of GC, at least for those GC that can be measured in
the blood stream. There is however an increasing number of
studies and experimental evidence that points towards
alternative sources of GC. Extra-adrenal GC synthesis was
initially described in the thymic epithelium, mostly by work
of Jonathan Ashwell and colleagues, and was later extended
to other organs [46]. Interestingly, although thymocytes
rapidly die by apoptosis in response to exogenous and
endogenous GC, in vivo and ex vivo experiments of
Ashwell and colleagues suggested that local thymic GC
synthesis is important for positive selection by lowering the
activation signal induced by the T cell receptor [46, 47].
These findings have been questioned by others though, and
the definite role of thymic GC synthesis remains to be
further investigated. However, clearly the thymic epitheli-
um expresses all the steroidogenic enzymes required to
synthesize GC and thus represents an extra-adrenal source
of GC [48, 49].
Subsequently, other tissues such as brain, skin, and
vascular endothelium have been described to express
steroidogenic enzymes and were claimed to be potential
extra-adrenal sources of GC [50]. So far, it has been difficult
to investigate the role of extra-adrenal GC synthesis in these
organs in vivo and to determine its relevance for health and
disease. A major problem in the investigation of extra-
adrenal GC synthesis is the fact that the adrenals, although a
tiny organ, are the most potent source for GC, which are
distributed to all peripheral tissues via the circulation.
Therefore, it is often difficult to distinguish between serum
contamination and local steroidogenesis in a given tissue.
Furthermore, it is very difficult to pharmacologically block
local GC synthesis while maintaining proper adrenal
function. In the future, the tissue-specific deletion of
steroidogenic enzymes may help to better define the role of
extra-adrenal GC synthesis in non-adrenal tissues and
determine its role for health and disease. Nonetheless, in
certain tissues, such as the intestine, investigations of extra-
adrenal GC synthesis have been possible in various
experimental models. These experiments have helped to
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reveal the important role of local GC synthesis in fine-tuning
local immune responses [16].
Intestinal epithelial cells as source of extra-adrenal GC
Accumulating evidence for the specific role and regulation
of local GC synthesis is available for the intestinal mucosa.
Already in 1995 it was reported by Keith Parker and
colleagues that the cholesterol side-chain cleavage enzyme
P450scc (CYP11A1), converting cholesterol to pregneno-
lone, is expressed in the primitive gut of the mouse embryo,
suggesting that the intestinal mucosa may represent a
steroidogenic organ [51]. Later on, further evidence was
provided by a study from our lab for the synthesis and
action of intestinal GC. Intra-epithelial lymphocytes (IEL)
are T cells with a predominantly unconventional phenotype
that reside within the intestinal epithelial layer in direct
physical contact with the epithelial cells. Although most of
the IEL are CD8+, they show no cytotoxic potential but
rather exhibit a regulatory phenotype. Analysis of IEL
effector function is severely hampered by their rapid death
when cultured ex vivo. While studying the mechanisms of
IEL apoptosis, it was noticed that IEL are very sensitive to
GC-induced apoptosis and that in vivo treatment of mice
with the GR antagonist RU-486 significantly reduced ex
vivo apoptosis of IEL. In contrast, adrenalectomy only
weakly reduced IEL apoptosis, indicating that an alternative
source of GC, likely within the intestinal mucosa, may be
responsible for triggering IEL cell death [52].
As mentioned above and shown in Fig. 2, GC, such as
corticosterone and cortisol, are produced from cholesterol via
specific enzymatic pathways. Interestingly, in the murine
small or large bowel, only some of the steroidogenic
enzymes are constitutively expressed. Critically, some genes
encoding for these enzymes, in particular CYP11A1 (side
chain-cleaving enzyme, P450scc) and CYP11B1 (11β-
hydroxylase), are strongly induced upon activation of
immune cells. Notably, injection of an agonistic anti-CD3ε
antibody, leading to a rapid activation of T cells, results in a
strong upregulation of several steroidogenic enzymes in the
intestinal tissue within few hours, suggesting a counter-
regulatory reaction of the local tissue in response to strong
immune cell activation and initiation of inflammatory
processes. Upon immune cell activation, not only the
expression of steroidogenic enzymes is induced, but ste-
roidogenesis is actually initiated. Tissue samples from small
and large intestine can be isolated and cultured for a limited
time ex vivo. Interestingly, corticosterone produced in these
tissue samples is easily detectable by radioimmunoassay or
gas chromatography/mass spectrometry in the culture super-
natant. Importantly, GC measured are bona fide produced
within these intestinal tissue samples, as their synthesis is
blockable by addition of metyrapone, a specific inhibitor of
11β-hydroxylase and thus GC synthesis [16].
What is the relevant cellular source of intestinal GC?
The intestinal mucosa is a complex tissue comprising a
variety of different cell types. As in the adrenal glands, GC
are produced in epithelial cells: epithelial cells in the
intestinal mucosa are also a likely source of GC. Indeed, in
situ hybridization experiments as well as differential
isolation of cells from the intestinal mucosa revealed that
the expression of steroidogenic enzymes is defined to the
intestinal epithelial layer and more specifically to the
intestinal crypts [16, 53, 54]. As discussed later on, this
localized expression of steroidogenic enzymes is also
relevant for the adapted regulation of intestinal GC
synthesis, in comparison to that in the adrenal glands.
Differences in the regulation of adrenocortical versus
intestinal GC synthesis
Whereas the regulation of adrenal GC synthesis has been the
topic of extensive studies and many of the signaling pathways
involved have been identified so far, little is known regarding
the regulation of extra-adrenal GC synthesis. Mueller et al.
recently pointed out that the molecular basis of GC synthesis
in intestinal epithelial cells is substantially distinct from that in
adrenal cells, most likely indicating an adaptation to the
different local settings and requirements [55]. First evidence
for a local adapted intestinal GC synthesis is the differential
expression of the two orphan nuclear receptors SF-1
(steroidogenic factor-1, NR5a1) and its close homologue
Fig. 2 Simplified scheme of adrenal glucocorticoid synthesis in
humans and rodents
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LRH-1 (liver receptor homologue-1, NR5a2). SF-1 is a
critical transcription factor in the regulation of adrenal GC
synthesis [56]. Absence of SF-1 results in lack of adrenal
steroidogenesis and thereby in the absence of serum GC
[57]. Not surprisingly, SF-1 is abundantly expressed in the
adrenal gland. In sharp contrast, the intestine does not
express SF-1, but it seems to be functionally replaced by its
close homologue LRH-1 [55, 58]. Already previously, it has
been shown that CYP11A1 expression in the murine
embryonic gut is not dependent on SF-1, suggesting that
other transcription factors regulate the expression of ste-
roidogenic enzymes in this organ [51]. LRH-1 and SF-1
have a high sequence homology, overlapping activities, and
bind to the same consensus sequences in the promoter
regions of steroidogenic enzymes [59]. LRH-1, almost not
detectable in the adrenal glands, is abundantly expressed in
the intestinal crypts, where it regulates local GC synthesis. In
agreement with this role of LRH-1, it was found that over-
expression of LRH-1 in intestinal epithelial cells is sufficient
to induce the expression of steroidogenic enzymes and
trigger GC synthesis in vitro. More critically, LRH-1 haplo-
insufficiency (complete deficiency is embryonically lethal
[60]) severely impairs intestinal GC synthesis, e.g., as
induced by injection of anti-CD3ε antibodies, whereas
adrenal GC synthesis and systemic GC levels remain
unaffected [61].
This differential expression and use of critical regulators of
steroidogenesis in the adrenals versus the intestinal epithelium,
i.e., SF-1 versus LRH-1, strongly argues for a substantially
different regulation of the adrenal versus the intestinal GC
synthesis. It further points out that this differential regulation is
likely the result of different needs for the systemic and the
intestinal GC synthesis. Clearly, adrenal GC synthesis must be
very rapid and very strong to provide the body with sufficient
levels of GC within a minimal amount of time. In contrast,
velocity of intestinal GC synthesis may not be so critical but
rather the appropriateness of its induction to allow or prevent
local immune responses. Furthermore, constitutive low levels
of intestinal GC may also be required to maintain optimal
intestinal barrier functions. It is thus interesting to note that GC
regulate the expression of tight junction proteins [62, 63].
A major difference in the regulation of intestinal versus
adrenal GC synthesis is the respective role of the cAMP
signaling pathway. It is well established that adrenal
steroidogenesis is critically regulated by the peptide
hormone ACTH [64]. The activation of the ACTH receptor
leads to the activation of the adenylate cyclase and the
formation of cAMP [65]. This in turn is critical for the
activation of protein kinase A and subsequently the in-
duction of a variety of steroidogenic enzymes, in particular
of the cytochrome P450 family, via so-called CRE in their
promoters [66].The ACTH signaling pathway can be easily
mimicked by treating cells with cell-permeable cAMP (e.g.,
8-bromo-cAMP) or forskolin, which leads to an increase in
intracellular cAMP levels. Surprisingly, while these triggers
induce the expression of steroidogenic enzymes and GC
synthesis in adrenal cell lines, they have completely the
opposite action in intestinal epithelial cells. Instead of
inducing steroidogenesis, cAMP treatment even leads to an
inhibition of basal and LRH-1-driven GC synthesis. A
reciprocal finding is observed when treating the cells with
phorbol ester. Phorbol ester, such as phorbol myristate
acetate (PMA), are well-known activators of protein
kinases, e.g., members of the protein kinase C family.
Interestingly, in adrenal cells, PMA has little effect on
steroidogenesis or even an inhibitory action. In marked
contrast, PMA treatment enhances both basal as well as
LRH-1-driven expression of steroidogenic enzymes and GC
synthesis in intestinal epithelial cells [55]. Likely, this is
due to specific activation of LRH-1. Although crystal
structure analysis of LRH-1 revealed putative ligands
(e.g., phospholipids) whose binding might regulate LRH-1
transcriptional activity, at least murine LRH-1 can be
activated ligand-independently [39, 67]. In contrast, the
MAP kinase-mediated phosphorylation of the hinge region
of LRH-1 appears to be important for the regulation of
LRH-1 activity [68]. As PMA is a potent activator of the
MAP kinase pathway, it is likely that PMA affects LRH-1
activity by inducing its phosphorylation [69]. While the
actual molecular mechanism of cAMP-mediated inhibition
and PMA-induced activation of intestinal GC synthesis are
currently not fully understood, these findings further
support the different requirements of and regulation of
intestinal versus adrenal steroidogenesis.
LRH-1, cell cycle, and GC synthesis
LRH-1 has not only been implicated in the regulation of
steroidogenesis but also in other cellular processes. Of note is
a recent finding by Botrugno and colleagues who reported that
LRH-1 may be critical for intestinal crypt cell proliferation by
inducing cyclin D1 and E1 expression [70]. Not surprisingly,
it was further found that LRH-1 may also promote the
development of intestinal epithelial tumors [71]. Thus, LRH-
1 appears to regulate intestinal epithelial layer integrity via
two distinct processes. Upon epithelial damage, LRH-1-
induced proliferation of crypt cells may help to close the
gaps and to recover intestinal epithelial barrier functions. In
agreement with its cell cycle-regulating role, we observed
that LRH-1 is predominantly expressed in the proliferating
cells of the crypts and is lost in the differentiated cells of the
villus [53]. On the other hand, LRH-1 likely contributes to
epithelial layer repair by the regulation of intestinal GC
synthesis, thereby inhibiting inflammatory process and
inducing TJ proteins [62] (Fig. 3).
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There is yet another interesting connection between
LRH-1 and cell cycle. Clearly, LRH-1 should exclusively
be active in the crypt region in order to prevent uncon-
trolled cyclin expression and cell cycle progression, and
thereby promote tumorigenesis. A similar pattern is seen
when LRH-1-induced steroidogenesis is assessed. Inhibi-
tion of cell cycle progression by either pharmacological or
biological cell cycle inhibitors not only blocks cell cycle
progression of crypt cell-like epithelial cells but also
strongly inhibits LRH-1 transcriptional activity, the expres-
sion of steroidogenic enzymes, and the synthesis of GC.
Similarly, epithelial cell differentiation seems to limit the
activity of LRH-1 and thereby the transcription of target
genes such as cyclin D1, E1, and steroidogenic enzymes.
For example, the differentiation of the colonic crypt cell
line YAMC leads to cell cycle arrest, an upregulation of the
cell cycle inhibitor p21 and a downregulation of cyclin D1
and CYP11B1 [53]. This in vitro finding probably
recapitulates what is likely to happen when undifferentiated
crypt cells differentiate to more mature absorptive epithelial
cells. Indeed, LRH-1, cyclin D1, and steroidogenic enzyme
expression is largely restricted to the proliferating cells of
the crypts and gets gradually lost towards the villus tip [16,
53]. This effect may largely restrict the expression of
steroidogenic enzymes and intestinal GC synthesis to the
self-renewing pool of epithelial stem cells and thereby
further help to maintain epithelial layer integrity.
Intestinal GC synthesis and the regulation of local
immune responses
Due to their potent anti-inflammatory actions, GC have
important therapeutic applications in the treatment of
inflammatory disorders, including those of the intestinal
mucosa. Thus, GC are first-line therapeutic agents for the
treatment of ulcerative colitis (UC) and Crohn's Disease
(CD) [72]. Independently of the route of application, GC
rapidly improve the outcome of moderate to severe acute
UC and CD, most probably by dampening overwhelming
immune responses in the inflamed intestine. Also in the
normal mucosa, the intestinal immune system is confronted
with the difficult task to protect the intestinal mucosa while
maintaining immune homeostasis and to avoid overshoot-
ing immune responses. These processes are tightly regulat-
ed by a variety of mechanisms. Intestinal epithelial cells
appear to critically contribute to the maintenance of
intestinal immune homeostasis via the production of extra-
adrenal GC [8].
Role of local GC synthesis in the regulation of intestinal
antiviral immune responses
Viral infections often elicit strong and protective immune
responses, which may however also result in tissue
destruction and immunopathology. This is particularly
evident in the liver where the antiviral immune response
rather than the viral infection per se leads to hepatitis-
associated tissue damage [73]. The local production of GC
may help to dampen such strong immune responses and to
protect the tissue from uncontrolled damage. The hypoth-
esis that intestinal GC synthesis may regulate local antiviral
immune responses was recently tested by Cima et al. [16].
Infection of mice with lymphocytic chorionmeningitis virus
leads to rapid spreading and replication of the virus in
various organs, including the intestinal mucosa. The strong
activation and expansion of cytotoxic antiviral CD8+ T
cells is subsequently responsible for the elimination of
virus-infected cells and the clearance of the virus. Employ-
ing this system, it was noted that in the absence of local GC
synthesis, the activation of virus-specific intestinal T cells
was significantly more pronounced. Antigen-specific T
cells isolated from the epithelial layer, the lamina propria
as well as from Peyer's patches expressed significantly
higher levels of the activation marker CD69 and produced
more IFNγ when local GC synthesis was blocked. Thus,
locally produced GC seem to act on gut-homing antigen-
specific T cells in a paracrine manner by substantially
buffering their activation potential.
Intestinal GC synthesis during inflammatory bowel disease
In general viral infections, antiviral immune responses and
associated immunopathologies are only transient. Much in
contrast, uncontrolled inflammatory disorders of the intes-
tinal mucosa often result in chronic self-amplifying dis-
orders, e.g., as observed in IBD. It is thus of major interest
to understand to which extent intestinal GC synthesis
Fig. 3 The role of LRH-1 in intestinal epithelial cells. A simplified
scheme of the intestinal crypt region illustrates the dual role of LRH-1
in the intestine by promoting cell proliferation to maintain epithelial
barrier integrity and by inducing intestinal steroidogenesis
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contributes to the regulation of the pathogenesis of IBD.
Coste et al. recently investigated this issue indirectly by
investigating the role and impact of LRH-1 in the regulation
of experimental IBD and in human IBD patients [61]. The
induction of experimental colitis in wild-type mice led to a
substantial upregulation of mRNA transcripts for steroido-
genic enzymes as well as to a clear induction of in situ
synthesized intestinal GC, suggesting intestinal GC synthe-
sis as part of a negative feedback response. In contrast,
steroidogenic enzyme expression and intestinal GC synthe-
sis was significantly reduced in LRH-1 haplo-insufficient
mice or mice with tissue-specific deletion of LRH-1,
confirming the important role of LRH-1 in the regulation
of intestinal GC synthesis. Importantly, absence of LRH-1
in the intestinal epithelium led to an increased susceptibility
to dextran sodium sulfate (DSS)- and TNBS-induced colitis
and an exacerbation of immunopathology. Colitogenic
LRH-1-deficient mice were characterized by increased
infiltration of mononuclear cells and a boost in colonic
pro-inflammatory cytokine mRNA expression compared to
wild-type controls. Interestingly, these experimental data
could be confirmed by expression data in human patients
with UC and CD, in which reduced levels of LRH-1 and
steroidogenic enzymes, but increased expression of pro-
inflammatory cytokines, were observed in colonic biopsies
of inflamed tissue compared to healthy tissue [61].
In line with the results of Coste et al., we recently
described the induction of steroidogenic enzymes and
associated GC synthesis in different animal models of
colitis, i.e., DSS-, TNBS-, and oxazolone-induced colitis.
Interestingly, the induction of colitis-associated GC synthe-
sis seems not to be dependent on the induction of
inflammation per se but on the type of inflammation.
Whereas all three models of colitis led to profound colonic
inflammation with massive leukocyte infiltration and
epithelial layer damage, the induction of intestinal GC
synthesis was quite distinct in the different model systems.
Whether or not intestinal steroidogenesis was induced
seemed to depend on the cytokine profile produced and
more specifically on the presence of specific pro-
inflammatory cytokines. Thus, DSS and TNBS, which
induce a Th1 cytokine profile, promoted intestinal GC
synthesis, whereas oxazolone, inducing a Th2 cytokine
profile, failed to do so (Noti M, Brunner T, unpublished
data).
TNFα as critical regulator of intestinal GC synthesis
TNFα is a well-characterized pro-inflammatory cytokine
with a critical role in the pathogenesis of inflammatory
bowel disease (IBD) [74]. In particular, TNFα appears to be
important for the initiation of the intestinal inflammation
[75]. Consequently, absence or neutralization of TNFα
ameliorates disease progression in different (but not all)
experimental colitis models and human patients [76, 77].
Treatment of IBD patients with the neutralizing anti-TNFα
antibody Infliximab has astonishing beneficial effects and is
surprisingly long lasting. This has led to the hypothesis
that Infliximab may not only neutralize soluble TNFα but
likely also target transmembrane TNFα-expressing immune
cells by inducing cell death [78]. Clearly, these findings
illustrate the potent pro-inflammatory properties of TNFα
in IBD.
Apart the well-known pro-inflammatory actions of
TNFα, there is increasing evidence for various anti-
inflammatory effects of this cytokine [76, 79]. While part
of this activity was attributed to direct apoptosis induction
or sensitization to apoptosis induction by other triggers,
other mechanisms are also likely involved [80, 81]. We and
others recently showed that lack of TNFα exacerbates
disease progression in DSS-induced colitis ([76] and
unpublished data). TNFα seems to have a protective effect
in DSS-induced colitis as absence of TNFα leads to
increased weight loss and significantly higher colonic
myeloperoxidase levels, indicative of neutrophilic infiltra-
tion, compared to DSS-treated wild-type animals. While in
wild-type animals the onset of the disease was paralleled by
a time-dependent increase in colonic GC synthesis, ste-
roidogenic enzyme expression and associated intestinal GC
synthesis were drastically reduced in TNFα-deficient
animals despite the pronounced induction of colonic
inflammation. The importance of TNFα in the induction
of intestinal GC synthesis could be confirmed by a
significant reduction in steroidogenic enzyme expression
and intestinal GC synthesis in TNFα-deficient animals in
response to strong in vivo T cell activation, i.e., injection of
the agonistic anti-CD3ε antibody. Similarly, direct injection
of TNFα in healthy animals leads to a pronounced
induction of intestinal GC synthesis, confirming its direct
activity on intestinal steroidogenesis (Noti M, Brunner T,
unpublished data; Fig. 4).
This novel view of the anti-inflammatory activity of
TNFα also opens new perspectives. As discussed above, a
Th2 cytokine-mediated experimental form of colitis in-
duced by oxazolone failed to promote colonic GC synthe-
sis. This is likely due to the absence of TNFα and an
overproduction of Th2 cytokines, such as IL-4. Remark-
ably, therapeutic treatment of mice with oxazolone colitis
with recombinant TNFα restores steroidogenic enzyme
expression, colonic GC synthesis, and significantly ameli-
orates the clinical parameters in treated animals. While
TNFα has been previously associated with the induction of
cachexia [82] and was therefore considered an inducer of
body weight loss, daily treatment of colitogenic mice
with recombinant murine TNFα significantly reduced
oxazolone-induced body weight loss and led to overall
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improved tissue pathology and colitis score. Thus, TNFα
appears to have a novel, rather paradoxical, anti-
inflammatory activity in the intestinal mucosa via the
induction of GC synthesis in intestinal epithelial cells.
Importantly, so far all previously described anti-
inflammatory properties of TNFα have been attributed to
act on T cells. These findings now provide evidence for an
alternative pathway via the induction of intestinal steroido-
genesis. While experiments with epithelial cell lines in vitro
prove that TNFα can directly induce the expression of
steroidogenic enzymes in these cells, the exact mode of
action and associated mechanisms of TNFα-induced or
TNFα-mediated intestinal GC synthesis remain to be
elucidated but offer novel opportunities for therapeutic
intervention.
GC and their beneficial effect on intestinal epithelial barrier
integrity
While intestinal GC likely have an immunoregulatory
activity on local and infiltrating immune cells and thus on
the development of intestinal inflammation, intestinal GC
synthesis may affect local inflammation also by other
means. Therapeutic administration of GC has been reported
to induce intestinal tight junction (TJ) proteins and improve
epithelial barrier functions in CD patients. Normalization of
the intestinal permeability correlated directly with clinical
amelioration of the disease and is a positive predictor of
prolonged clinical remission [23, 40]. As colitis affects
severely the intestinal epithelium, Boivin et al. investigated
the role of exogenously administered GC on the integrity of
the intestinal epithelial TJ by using an intestinal epithelial
cell line [62]. Strikingly, they observed that, in Caco-2
cells, GC inhibited TNFα-induced increase in myosin light
chain kinase (MLCK) expression, which plays a major role
in mediating increased intestinal TJ permeability. It has
been previously shown that myosin light chain phosphor-
ylation by MLCK is responsible for TJ disruption and
increased epithelial layer permeability. Both genetic and
pharmacological MLCK inhibition prevented in vivo
epithelial barrier dysfunction following systemic T cell
activation [83]. Local intestinal GC synthesis, as induced
upon induction of intestinal inflammation, may therefore
attenuate TNFα-mediated TJ barrier disruption by inhibit-
ing TNFα-induced MLCK expression. Thus, TNFα may
again play a dual role in intestinal inflammation, on one
hand a pro-inflammatory by inducing immune cell activa-
tion and disrupting the epithelial barrier function, on the
other hand an anti-inflammatory via the induction of
intestinal GC, inhibition of immune cell functions, and
repair of epithelial barrier functions. Likely, the orchestrat-
ed action of TNFα in time and space may be critical for the
dissociation between these pro- and anti-inflammatory
properties.
Fig. 4 Regulation of intestinal glucocorticoid synthesis by TNFα.
Alterations in epithelial barrier integrity lead to the activation of
intestinal immune cells releasing pro-inflammatory cytokines such as
TNFα, which further amplifies the local immune response and
associated immune cell-mediated tissue damage. Intestinal epithelial
cells counter-regulate an overwhelming immune response by releasing
immunoregulatory factors. TNFα directly induces steroidogenesis in
intestinal epithelial cells leading to the secretion of immunoregulatory
glucocorticoids. Glucocorticoids regulate the activation of transcrip-
tion factors, such as AP-1 or NFκB (transrepression), leading to
reduced production of pro-inflammatory cytokines. DC dendritic cells,
GC glucocorticoids, GR glucocorticoid receptor, MΦ macrophage, TJ
tight junction
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Tumor-produced GC as a novel mechanism of immune
escape?
As discussed above, LRH-1 is not only an essential
regulator of intestinal GC synthesis, but has also important
functions in promoting epithelial cell renewal and if
uncontrolled in the development of intestinal tumors [71].
Thus, LRH-1 may be considered as proto-oncogene. This
tumor-promoting effect of LRH-1 is at least in part
mediated by the induction of cyclin D1 and E1 expression
and uncontrolled cell cycle progression [70]. LRH-1-driven
GC synthesis by intestinal tumor cells may, however,
further contribute to immune escape of transformed cells
and the development of colon carcinoma. It is of interest
that the degree of infiltration of colon carcinoma with T
cells negatively correlates with the overall survival of tumor
patients [84], suggesting that immune evasion, e.g., via GC-
mediated suppression of immune cells, may be an effective
strategy of intestinal tumors.
We recently tested this hypothesis and assessed the
steroidogenic potential of colon carcinoma cells lines and
also primary tumors. Interestingly, most colon cancer cell
lines and basically all tumor samples expressed LRH-1 and
key steroidogenic enzymes required for GC synthesis (i.e.,
CYP11A1, CY17, CYP11B1). Furthermore, over-expression
of LRH-1 in colon cancer cell lines strongly induced the
expression of these steroidogenic enzymes, suggesting that
colon carcinomas are capable of synthesizing GC. Indeed, it
was found that, in colon cancer cell lines as well as in
primary tumors, the synthesis of cortisol can be measured by
radioimmunoassay, bioassay, as well as by monitoring the
conversion of radiolabeled 14C-progesteron to 14C-cortisol
using thin-layer chromatography (D. Sidler, T. Brunner,
unpublished data). Interestingly, when comparing the GC
synthesis potential, it was noted that ex vivo culture of
colonic tumor samples generally resulted in higher GC
concentrations produced than in normal mucosa specimens
from the same patient. These findings demonstrate that
transformed intestinal epithelial cells, such as colon carcino-
ma, have maintained the capability to produce GC and
further suggest that tumor-derived GC may contribute to
cancer development by promoting immune escape.
Conclusions
The data discussed above clearly demonstrate that the
intestinal mucosa and more specifically the intestinal
epithelial layer are a complete steroidogenic tissue capable
of synthesizing immunoregulatory GC in response to
qualitatively distinct immune responses. There is further
accumulating evidence that intestinal GC are intimately
involved in the regulation of intestinal immune homeostasis
and that disruption of critical elements in the GC synthesis
pathway in intestinal epithelial cells may lead to an
exacerbation of inflammatory responses and increased
tissue damage. While the enzymatic cascade and the end
product of adrenal and intestinal GC synthesis remain the
same, and adrenal and intestinal GC likely also have the
same effect on immune cell activation, there is also good
evidence that the regulation of intestinal GC synthesis is
substantially different from that in the adrenal glands. Two
key decision-making molecules appear to be the nuclear
receptor LRH-1 and the cytokine TNFα. While LRH-1 has
been shown to be critical for the transcriptional regulation
of steroidogenic enzymes, the direct mechanism of TNFα-
mediated activation of intestinal steroidogenesis remains to
be investigated. The characterization of intestinal GC
synthesis leads to the identification of a novel immunoreg-
ulatory mechanism in the intestinal mucosa and offers
novel targets for therapeutic intervention in the pathogen-
esis of inflammatory disorders of the intestine.
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